Status:
WITHDRAWN
High Flow Therapy (HFT) to Treat Respiratory Insufficiency in Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Vapotherm, Inc.
Conditions:
Pulmonary Disease, Chronic Obstructive
Respiratory Insufficiency
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The aim of this study is to see if the Vapotherm High Flow Therapy (HFT) device is effective to provide breathing support to patients with Chronic Obstructive Pulmonary Disease or COPD. The investigat...
Detailed Description
The overall objective of this study is to demonstrate that Vapotherm High Flow Therapy (HFT) via nasal cannula provides respiratory support to patients with COPD as a primary diagnosis, who present wi...
Eligibility Criteria
Inclusion
- Present to the Emergency Department with a history of COPD and with symptoms consistent with a diagnosis of respiratory insufficiency and exacerbation of COPD
- Must be hemodynamically stable as judged by treating clinician in the ED
- Primary complaint is shortness of breath, and presumed diagnosis is exacerbation of COPD
Exclusion
- Fever
- Radiographic evidence of pneumonia
- Glasgow Coma score \< 14 or unable to correctly answer at least one study-specific question
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00990119
Start Date
September 1 2009
End Date
April 1 2014
Last Update
September 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140